prikaz prve stranice dokumenta Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
  Download
PDF 5.37 MB
Scientific paper - Original scientific paper
Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
Croatian Medical Journal, 63 (2022), 2; 126-140. https://doi.org/10.3325/cmj.2022.63.126
Ramić, Snježana; Paić, Frane; Smajlbegović, Velda; Perić Balja, Melita; Hiršl, Lea; Marton, Ingrid; Knežević, Fabijan

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Ramić, S., Paić, F., Smajlbegović, V., Perić Balja, M., Hiršl, L., Marton, I. & Knežević, F. (2022). Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients. Croatian Medical Journal, 63. (2), 126-140. doi: 10.3325/cmj.2022.63.126

Ramić, Snježana, et al. "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients." Croatian Medical Journal, vol. 63, no. 2, 2022, pp. 126-140. https://doi.org/10.3325/cmj.2022.63.126

Ramić, Snježana, Frane Paić, Velda Smajlbegović, Melita Perić Balja, Lea Hiršl, Ingrid Marton and Fabijan Knežević. "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients." Croatian Medical Journal 63, no. 2 (2022): 126-140. https://doi.org/10.3325/cmj.2022.63.126

Ramić, S., et al. (2022) 'Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients', Croatian Medical Journal, 63(2), pp. 126-140. doi: 10.3325/cmj.2022.63.126

Ramić S, Paić F, Smajlbegović V, Perić Balja M, Hiršl L, Marton I, and sur.. Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients. Croatian Medical Journal [Internet]. 2022 April 30 [cited 2024 November 20];63(2):126-140. doi: 10.3325/cmj.2022.63.126

S. Ramić, et al., "Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients", Croatian Medical Journal, vol. 63, no. 2, pp. 126-140, April 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:519799. [Accessed: 20 November 2024]

Metadata
Title (english)Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
AuthorSnježana Ramić
AuthorFrane Paić
AuthorVelda Smajlbegović
AuthorMelita Perić Balja
AuthorLea Hiršl
AuthorIngrid Marton
AuthorFabijan Knežević
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Medical Biology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Medical Biochemistry
Abstract (english)
Aim: To determine the predictive value of phosphorylated human epidermal growth factor receptor 2 (pHER2Y1248) status in breast cancer (BC) patients undergoing trastuzumab-based adjuvant therapy. ----- Methods: Immunohistochemical status of pHER2Y1248, EGFR/HER1, HER3, and HER4 was determined in 124 consecutive HER2-positive BC patients (median age [range]=57 years [49.0-64.0]) treated at the University Hospital for Tumors, Zagreb, between 2008 and 2011. The median follow-up was 84 months (60.0-84.0). Prognostic factors of disease free survival (DFS) rate were evaluated with Kaplan-Meier/log-rank test and Cox regression analysis. ----- Results: pHER2Y1248, HER1, HER3, and HER4 were expressed in 66.1%, 9.7%, 70.2%, and 71.0% of patients, respectively. Disease progression (DP) was observed in 17.1% of pHER2Y1248-positive and 47.6% of pHER2Y1248-negative BCs (P=0.001). Kaplan-Meier analysis showed a worse five-year DFS in pHER2Y1248-negative patients who were older than 60 years (P<0.001) and had positive lymph node status (P<0.001); tumor size >2.0 cm (P<0.001); higher histological grade (P<0.001); HER2E intrinsic subtype (P<0.001), negative hormone receptors (P<0.001); negative HER1 status (P<0.001), positive HER3 (P=0.002); and/or positive HER4 (P=0.002) status. The only negative prognostic factor for five-year DFS in multivariate Cox regression analysis was pHER2Y1248-negative (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.8-7.2, P<0.001) and lymph node-positive status (HR 3.6, 95% CI 1.3-9.8, P=0.014). ----- Conclusion: pHER2Y1248 predicts sensitivity to trastuzumab and a better five-year DFS regardless of any other prognostic parameter. In HER2-positive BC patients. Non-phosphorylated HER2Y1248 is a strong predictor of trastuzumab resistance and a poor DFS.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCroatian Medical Journal
Numberingvol. 63, no. 2, pp. 126-140
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2022.63.126
URN:NBNurn:nbn:hr:105:519799
Publication2022-04-30
Document URLhttp://www.cmj.hr/2022/63/2/35505646.htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2022-05-20 10:14:43